INTELLIA THERAPEUTICS INC (NTLA)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for NTLA
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| NTLA | Director | ["Held international senior management positions with Merck","Vice president, hypertension, worldwide human health marketing at Merck","Managing director of Merck’s Dutch subsidiary","International leadership positions at Servier Laboratories","Current board member of Bavarian Nordic A/S and Capsida Biotherapeutics Inc.","Former chairman of the board of Avidicure","Former board member of ObsEva SA and the Biotechnology Innovation Organization","M.D. from Erasmus University, Rotterdam","M.B.A. from INSEAD"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Dr. Verwiel served on the audit committee throughout 2025 and on the nominating and corporate governance committee throughout 2025, serving as committee chair of the nominating and corporate governance committee. Our board of directors has determined that Dr. Verwiel is independent for audit committee purposes as that term is defined in the applicable rules of the SEC and Nasdaq.